Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US

Enrolment of Patients with DMD in the US Expected to Start 3Q 2016Utrophin Modulation Offers Differentiated Approach in DMD OXFORD, United Kingdom, April 26, 2016 (GLOBE NEWSWIRE) -- Summit...
March 30, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD

OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...